Pemetinib/pemetinib: a pioneer in anti-cancer targeting FGFR targets

Pemigatinib/Pemigatinib has emerged in the field of tumor treatment with its precise inhibitory effect on fibroblast growth factor receptor (FGFR). As a small molecule kinase inhibitor, pemetinib effectively inhibits the growth and spread of tumor cells by blocking the FGFR signaling pathway.

FGFR is a target overexpressed on the surface of various tumor cells and is closely related to the occurrence, development and malignant transformation of tumors. Pemetinib can specifically bind to FGFR and significantly inhibit the activities of FGFR1, FGFR2 and FGFR3 at very low concentrations (IC50 less than 2nM). This powerful inhibitory effect allows pemetinib to exhibit excellent anti-tumor effects in tumor models with FGFR alterations.

Not only in laboratory studies, pemetinib has also achieved impressive results in clinical trials. Pemetinib has shown significant clinical efficacy in patients carrying FGFR mutations, providing new treatment hope for these patients. Based on its excellent performance, the U.S. Food and Drug Administration (FDA) approved pemetinib as the first targeted therapy for advanced cholangiocarcinoma in 2020, and in August 2022, further approved it for the treatment of relapsed or refractory myeloid/lymphoid tumors (MLNs) with FGFR1 rearrangements.

Currently, multiple ongoing clinical trials are evaluating the potential of pemetinib alone or in combination with other therapeutic agents to treat various cancers. These trials cover a variety of cancer types that do not respond to standard therapies or have FGFR mutations, including non-small cell lung cancer (NSCLC), bladder cancer, gastric cancer, colorectal cancer, and glioma. With further research, pemetinib is expected to provide effective and personalized treatment options for more patients.